News
Public · Published
Faeth Therapeutics: Cash, Cash Equivalents and Marketable Securities Were $174.8M as of Sept 30 >FTH
Faeth Therapeutics reported that its cash, cash equivalents and marketable securities totaled $174.8M as of September 30.
Published:
Updated:
What happened
Faeth Therapeutics reported that its cash, cash equivalents and marketable securities totaled $174.8M as of September 30.
Confirmed
Global impact / market context
This cash figure matters because it shows how much money Faeth has available to fund operations. The amount reflects cash and investments that can be converted to cash, which affects how long it can pay for research and other costs.
Analyst inference
Faeth Therapeutics appears in a Dow Jones market news item focused on its cash position. Investors often compare a company's cash available against its spending needs to judge whether it may need to raise outside money.
Analyst inference
What to watch
- Watch the September 30 total of $174.8M in cash, cash equivalents and marketable securities, which are investments that can be sold for cash. Confirmed
- Track whether Faeth provides updates on how much cash it uses over time, which would show how quickly the $174.8M balance may change. Proposed
- Monitor any sign that Faeth needs to raise more money or adjust spending, since a shrinking cash balance can affect research plans and costs. Analyst inference
Evidence
- Original source link unavailable